Does ertapenem alter the susceptibility of pseudomonas aeruginosa to carbapenems?

Journal of Chemotherapy

Volumn 23, Issue 4, 2011, Pages 216-220

  Beovic, B ^a   Kreft, S ^b   Seme, K ^b   Clzman M ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Antibiotic susceptibility; Ertapenem; Pseudomonas aeruginosa

Indexed keywords

CARBAPENEM; ERTAPENEM; ANTIINFECTIVE AGENT; BETA LACTAM; CARBAPENEM DERIVATIVE;

ABDOMINAL SURGERY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG EFFECT; HUMAN; INFECTION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; NONHUMAN; PREDICTION; PSEUDOMONAS AERUGINOSA; TEACHING HOSPITAL; DRUG INTERACTION; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CARBAPENEMS; DRUG INTERACTIONS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 80052756408     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.4.216     Document Type: Article

References (12)

1. Shah P, Isaacs RD. Ertapenem, the first of a new group of carbapen-ems. J Antimicrob Chemother 2003; 52 (4): 538-342.
2. Livermore DM, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005; 55 (3): 306-311.
3. Anon. EARSS Annual report 2008. Available at: http://www.rivm.nl/earss/result/Monitoring_reports/. (online).
4. DiNubile MJ, Friedland I, Chan YC, Motyl MR, Giezek H, Shivaprakash M, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis 2005; 24 (7):443-449.
5. Anon. ATC/DDD Index 2010. Available at http://www.whocc.no/atc_ddd_index/.
6. Clinical and Laboratory Standards Institute (CLS1). Performance standards for antimicrobial susceptibility testing-fifteenth informational supplement: M100-S15. Wayne, PA: CLSI. 2005.
7. Clements A, Halton K, Graves N, Pettitt A, Morton A, Looke D, et al. Overcrowding and understating in modern health-care systems: key determinants in methicillin-resistant Staphylococcus aureus transmission. Lancet Infect Dis 2008; 8 (7): 427-434.
8. Lima ALL, Oliveira PR, Paula AP, Del-Paz K, Rossi F, Zumiotti AV. 2009. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study. Infect Control Hosp Epidemiol 2009; 30 (5): 487-490.
9. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restrictions in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53 (5): 1983-1986.
10. Goff DA, Mangino JE. Ertapenem: no effect on anerobc gram-negative susceptibilities to imipenem. J Infect 2008; 57 (2): 123-127.
11. Goldstein EJC, Citron DM, Peraino V, Elgourt T, Meibohm AR, Lu S. Introduction of ertapenem into hospital formulary: effect on antimicrobial usage and improved in vitro susceptibility of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53 (12): 5122-5126.
12. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2005; 34 (5): 634-640.